Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer

Bing Liu; Daniela Duenas; Li Zheng; Karen Reckamp; Binghui Shen

doi:10.1007/s13238-021-00855-6

Bing Liu, Daniela Duenas, Li Zheng, Karen Reckamp, Binghui Shen. Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer[J]. Protein&Cell, 2022, 13(2): 82-89. doi: 10.1007/s13238-021-00855-6

Citation:

Bing Liu, Daniela Duenas, Li Zheng, Karen Reckamp, Binghui Shen. Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer[J]. Protein&Cell, 2022, 13(2): 82-89. doi: 10.1007/s13238-021-00855-6

Citation:

Bing Liu, Daniela Duenas, Li Zheng, Karen Reckamp, Binghui Shen. Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer[J]. Protein&Cell, 2022, 13(2): 82-89. doi: 10.1007/s13238-021-00855-6

Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer

Graphical Abstract

Abstract

FullText(HTML)

References (55)

Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer

Catalog

Export File

Citation

Format

Content